[go: up one dir, main page]

WO2008033351A3 - Multimodal abuse resistant and extended release formulations - Google Patents

Multimodal abuse resistant and extended release formulations Download PDF

Info

Publication number
WO2008033351A3
WO2008033351A3 PCT/US2007/019745 US2007019745W WO2008033351A3 WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3 US 2007019745 W US2007019745 W US 2007019745W WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
multimodal
abuse resistant
release formulations
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019745
Other languages
French (fr)
Other versions
WO2008033351A2 (en
Inventor
Najib Babul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relmada Therapeutics Inc
Original Assignee
Theraquest Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Inc filed Critical Theraquest Biosciences Inc
Publication of WO2008033351A2 publication Critical patent/WO2008033351A2/en
Anticipated expiration legal-status Critical
Publication of WO2008033351A3 publication Critical patent/WO2008033351A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is in the field of oral, abuse resistant pharmaceutical compositions of abusable drugs, extended release pharmaceutical compositions of abusable drugs and extended release abuse resistant pharmaceutical compositions of abusable drugs and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.
PCT/US2007/019745 2006-09-11 2007-09-12 Multimodal abuse resistant and extended release formulations Ceased WO2008033351A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84339206P 2006-09-11 2006-09-11
US60/843,392 2006-09-11
US90798707P 2007-04-26 2007-04-26
US60/907,987 2007-04-26

Publications (2)

Publication Number Publication Date
WO2008033351A2 WO2008033351A2 (en) 2008-03-20
WO2008033351A3 true WO2008033351A3 (en) 2009-04-09

Family

ID=39184298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019745 Ceased WO2008033351A2 (en) 2006-09-11 2007-09-12 Multimodal abuse resistant and extended release formulations

Country Status (1)

Country Link
WO (1) WO2008033351A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
AU2007280636B2 (en) 2006-08-03 2013-07-18 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
KR101697773B1 (en) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. Modified release composition comprising doxofylline
US20120100212A1 (en) * 2009-07-06 2012-04-26 Kyorin Pharmaceutical, Co., Ltd. Tablet having hollow structure
AT509000B1 (en) * 2009-10-23 2012-12-15 Rausch Peter WATER-SOLUBLE PREPARATIONS OF CANNABINOIDS AND CANNABIC PREPARATIONS AND THEIR APPLICATIONS
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
FR2962550B1 (en) * 2010-07-06 2013-06-14 Ethypharm Sa METHOD FOR CONTROLLING CHEMICAL SUBMISSION, USE OF COLORING AGENT FOR COMBATING CHEMICAL SUBMISSION AND PHARMACEUTICAL COMPOSITION FOR THE IMPLEMENTATION OF THE METHOD
FR2962331B1 (en) * 2010-07-06 2020-04-24 Ethypharm PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION, METHOD USING THE SAME
EP2956440B1 (en) 2013-02-08 2018-04-11 General Mills, Inc. Reduced sodium food products
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN113473980A (en) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state
WO2021151169A1 (en) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Cannabinoid composition and manufacturing method
WO2021151168A1 (en) * 2020-01-31 2021-08-05 AusCann Group Holdings Ltd Method of cannabinoid therapy
CN117618393A (en) 2020-06-18 2024-03-01 凯瑞康宁生物工程（武汉）有限公司 Controlled release granulation of water-soluble active pharmaceutical ingredient
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202228665A (en) 2020-10-05 2022-08-01 凱瑞康寧生技股份有限公司 Modified release compositions of a gamma-hydroxybutyric acid derivative
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
EP4396305A4 (en) 2021-09-01 2025-08-27 Empathbio Inc SYNTHESIS OF MDMA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA ISOMERS
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
EP4457222A2 (en) 2021-12-28 2024-11-06 EmpathBio, Inc. Nitric oxide releasing prodrugs of mda and mdma
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms

Also Published As

Publication number Publication date
WO2008033351A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2007146248A3 (en) Stable laquinimod preparations
WO2008021394A3 (en) Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A3 (en) Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
ZA200901110B (en) Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
WO2007087431A3 (en) Sublingual fentanyl spray
WO2008024408A3 (en) Pharmaceutical formulations of cannabinoids for application to the skin and method of use
IL194954A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
AP2008004671A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP1993519A4 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2009081174A3 (en) Anti - retroviral combination
WO2008006795A3 (en) Indole compounds
WO2008003050A3 (en) Gallium nitrate formulations
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2005117895A3 (en) Compositions comprising meloxicam
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2009048940A3 (en) Diacerein pharmaceutical formulations
WO2008004100A9 (en) Therapeutic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838038

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838038

Country of ref document: EP

Kind code of ref document: A2